Nasdaq

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant ...

SAN DIEGO, June 27, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Seeking Alpha

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic ...
Times-Standard

Mad River Community Hospital deploys triage tent, limits patients’ visitors

From a Mad River Community Hospital release: Arcata, CA (March 23, 2020): Mad River Community Hospital, in response to the ever changing situation of COVID-19 and in an effort to protect staff, ...